Laekna Inc 02105
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- HK$5.16
- Day Range
- HK$5.23–5.88
- 52-Week Range
- HK$3.14–26.45
- Bid/Ask
- HK$5.57 / HK$5.58
- Market Cap
- HK$2.18 Bil
- Volume/Avg
- 4.6 Mil / 1.4 Mil
Key Statistics
- Price/Earnings (Normalized)
- 8.85
- Price/Sales
- —
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- 0.22%
Company Profile
Laekna Inc is a science-driven, clinical-stage biotechnology company. The company has established a comprehensive R&D infrastructure to accelerate the development of molecules from discovery to registrational trials. It has initiated one clinical trial and another five clinical trials for its Core Products LAE002 and LAE001. Among these six clinical trials, three multi-regional clinical trials (MRCTs) are designed to address medical needs in the standard of care (SOC)-resistant cancers. Laekna has two Core Products and 14 other pipeline product candidates. Core Product LAE002 is an adenosine triphosphate (ATP) competitive AKT inhibitor for the treatment of ovarian cancer, prostate cancer, breast cancer and PD-1/PD-L1 drug-resistant solid tumors.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- —
- Total Number of Employees
- 92
- Website
- https://www.laekna.com
Comparables
Valuation
|
Metric
|
02105
|
IMU
|
6550
|
|---|---|---|---|
Price/Earnings (Normalized) | 8.85 | — | — |
Price/Book Value | 3.00 | 2.97 | 5.94 |
Price/Sales | — | — | 625.56 |
Price/Cash Flow | — | — | — |
Price/Earnings
02105
IMU
6550
Financial Strength
|
Metric
|
02105
|
IMU
|
6550
|
|---|---|---|---|
Quick Ratio | 5.00 | 3.66 | 9.39 |
Current Ratio | 5.07 | 3.86 | 9.86 |
Interest Coverage | −140.41 | −321.34 | −41.75 |
Quick Ratio
02105
IMU
6550
Profitability
|
Metric
|
02105
|
IMU
|
6550
|
|---|---|---|---|
Return on Assets (Normalized) | −30.40% | −67.09% | −18.61% |
Return on Equity (Normalized) | −34.99% | −77.26% | −22.52% |
Return on Invested Capital (Normalized) | −35.28% | −79.58% | −21.09% |
Return on Assets
02105
IMU
6550
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Novo Nordisk AS ADR
NVO
| Tfrzjwskky | Kqtz | $531.4 Bil | |||
| Vertex Pharmaceuticals Inc
VRTX
| Ywxqckqky | Knldv | $119.5 Bil | |||
| Regeneron Pharmaceuticals Inc
REGN
| Zlxgtgdlx | Dshfvw | $114.9 Bil | |||
| Alnylam Pharmaceuticals Inc
ALNY
| Dtgzxnb | Yhfvg | $35.3 Bil | |||
| argenx SE ADR
ARGX
| Yqglphcc | Wwlnx | $32.0 Bil | |||
| BioNTech SE ADR
BNTX
| Ptxsrgv | Lpzh | $28.1 Bil | |||
| Moderna Inc
MRNA
| Gmrrdsgy | Fjzw | $25.3 Bil | |||
| United Therapeutics Corp
UTHR
| Twcrcpx | Brcxz | $16.0 Bil | |||
| Biomarin Pharmaceutical Inc
BMRN
| Mphmntl | Vfwctpq | $13.4 Bil | |||
| Incyte Corp
INCY
| Xbvjqxpvh | Xrvtx | $12.7 Bil |
United States